U2AF1 mutations alter sequence specificity of pre-mRNA binding and splicing

Leukemia

Volumn 29, Issue 4, 2015, Pages 909-917

  Okeyo Owuor, T ^a   White, B S ^a,b   Chatrikhi, R ^c   Mohan, D R ^a   Kim, S ^a   Griffith, M ^b   Ding, L ^b   Ketkar Kulkarni, S ^a   Hundal, J ^b   Laird, K M ^c   Kielkopf, C L ^c   Ley, T J ^a,b   Walter, M J ^a   Graubert, T A ^d  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTIDINE; MESSENGER RNA PRECURSOR; PHENYLALANINE; SERINE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR U2AF1; UNCLASSIFIED DRUG; URIDINE; CD34 ANTIGEN; NUCLEAR PROTEIN; PROTEIN BINDING; RIBONUCLEOPROTEIN; RNA PRECURSOR; U2AF1 PROTEIN, HUMAN;

ALTERNATIVE RNA SPLICING; AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; BINDING SITE; CD34 SELECTION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GENE EXPRESSION; GENE FUNCTION; GENETIC TRANSFECTION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MISSENSE MUTATION; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RNA BINDING; RNA SEQUENCE; CHEMISTRY; CYTOLOGY; FETUS BLOOD; GENETICS; METABOLISM; MOLECULAR GENETICS; MONONUCLEAR CELL; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PLASMID; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; SPLICEOSOME;

ALTERNATIVE SPLICING; ANTIGENS, CD34; BASE SEQUENCE; BINDING SITES; FETAL BLOOD; HUMANS; LEUKOCYTES, MONONUCLEAR; MOLECULAR SEQUENCE DATA; MUTATION; MYELODYSPLASTIC SYNDROMES; NUCLEAR PROTEINS; PLASMIDS; PRIMARY CELL CULTURE; PROTEIN BINDING; RIBONUCLEOPROTEINS; RNA PRECURSORS; SIGNAL TRANSDUCTION; SPLICEOSOMES; TRANSFECTION;

EID: 84927691315     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.303     Document Type: Article

References (35)

1. Graubert TA, Shen D, Ding L, Okeyo-Owuor T, Lunn CL, Shao J et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 2012; 44: 53-57.
2. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Sato Y et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478: 64-69.
3. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011; 365: 1384-1395.
4. Mian SA, Smith AE, Kulasekararaj AG, Kizilors A, Mohamedali AM, Lea NC et al. Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome. Haematologica 2013; 98: 1058-1066.
5. Visconte V, Makishima H, Jankowska A, Szpurka H, Traina F, Jerez A et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia 2012; 26: 542-545.
6. Makishima H, Visconte V, Sakaguchi H, Jankowska AM, Abu Kar S, Jerez A et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 2012; 119: 3203-3210.
7. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult De novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059-2074.
8. Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, Bassaganyas L et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2012; 44: 47-52.
9. Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011; 365: 2497-2506.
10. Rossi D, Bruscaggin A, Spina V, Rasi S, Khiabanian H, Messina M et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: Association with progression and fludarabine-refractoriness. Blood 2011; 118: 6904-6908.
11. Wu S, Romfo CM, Nilsen TW, Green MR. Functional recognition of the 3[prime] splice site AG by the splicing factor U2AF35. Nature 1999; 402: 832-835.
12. Ruskin B, Zamore PD, Green MR. A factor, U2AF, is required for U2 snRNP binding and splicing complex assembly. Cell 1988; 52: 207-219.
13. Zhang M, Zamore PD, Carmo-Fonseca M, Lamond AI, Green MR. Cloning and intracellular localization of the U2 small nuclear ribonucleoprotein auxiliary factor small subunit. Proc Natl Acad Sci 1992; 89: 8769-8773.
14. Zamore PD, Green MR. Identification, purification, and biochemical characterization of U2 small nuclear ribonucleoprotein auxiliary factor. Proc Natl Acad Sci 1989; 86: 9243-9247.
15. Berglund JA, Abovich N, Rosbash M. A cooperative interaction between U2AF65 and mBBP/SF1 facilitates branchpoint region recognition. Genes Dev 1998; 12: 858-867.
16. Rudner DZ, Breger KS, Kanaar R, Adams MD, Rio DC. RNA binding activity of heterodimeric splicing factor U2AF: At least one RS domain is required for highaffinity binding. Mol Cell Biol 1998; 18: 4004-4011.
17. Wu JY, Maniatis T. Specific interactions between proteins implicated in splice site selection and regulated alternative splicing. Cell 1993; 75: 1061-1070.
18. Prigge JR, Iverson SV, Siders AM, Schmidt EE. Interactome for auxiliary splicing factor U2AF65 suggests diverse roles. Biochim Biophys Acta 2009; 1789: 487-492.
19. Damm F, Kosmider O, Gelsi-Boyer V, Renneville A, Carbuccia N, Hidalgo-Curtis C et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood 2012; 119: 3211-3218.
20. Przychodzen B, Jerez A, Guinta K, Sekeres MA, Padgett R, Maciejewski JP et al. Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms. Blood 2013; 122: 999-1006.
21. Thol F, Kade S, Schlarmann C, Löffeld P, Morgan M, Krauter J et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012; 119: 3578-3584.
22. Walter MJ, Shen D, Shao J, Ding L, White BS, Kandoth C et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia 2013; 27: 1275-1282.
23. Jenkins JL, Shen H, Green MR, Kielkopf CL. Solution conformation and thermodynamic characteristics of RNA binding by the splicing factor U2AF65. J Biol Chem 2008; 283: 33641-33649.
24. Kobayashi H, Carbonaro D, Pepper K, Petersen D, Ge S, Jackson H et al. Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector. Mol Ther 2005; 11: 776-789.
25. Fu Y, Masuda A, Ito M, Shinmi J, Ohno K. AG-dependent 3?-splice sites are predisposed to aberrant splicing due to a mutation at the first nucleotide of an exon. Nucleic Acids Res 2011; 39: 4396-4404.
26. Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult De novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059-2074.
27. Reed R. The organization of 3' splice-site sequences in mammalian introns. Genes Dev 1989; 3: 2113-2123.
28. Pacheco TR, Coelho MB, Desterro JMP, Mollet I, Carmo-Fonseca M. In vivo requirement of the small subunit of U2AF for recognition of a weak 3? splice site. Mol Cell Biol 2006; 26: 8183-8190.
29. Guth S, Martínez C, Gaur RK, Valcárcel J. Evidence for substrate-specific requirement of the splicing factor U2AF35 and for its function after polypyrimidine tract recognition by U2AF65. Mol Cell Biol 1999; 19: 8263-8271.
30. Brooks AN, Choi PS, De Waal L, Sharifnia T, Imielinski M, Saksena G et al. A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events. PLoS One 2014; 9: E87361.
31. Chusainow J, Ajuh PM, Trinkle-Mulcahy L, Sleeman JE, Ellenberg J, Lamond AI. FRET analyses of the U2AF complex localize the U2AF35/U2AF65 interaction in vivo and reveal a novel self-interaction of U2AF35. RNA 2005; 11: 1201-1214.
32. Gama-Carvalho M, Krauss RD, Chiang L, Valcárcel J, Green MR, Carmo-Fonseca M. Targeting of U2AF65 to sites of active splicing in the nucleus. J Cell Biol 1997; 137: 975-987.
33. Webb CJ, Wise JA. The splicing factor U2AF small subunit is functionally conserved between fission yeast and humans. Mol Cell Biol 2004; 24: 4229-4240.
34. Lai WS, Kennington EA, Blackshear PJ. Interactions of CCCH zinc finger proteins with mRNA: Non-binding tristetraprolin mutants exert an inhibitory effect on degradation of Au-rich element-containing mRNAs. J Biol Chem 2002; 277: 9606-9613.
35. Liang J, Song W, Tromp G, Kolattukudy P, Fu M. Genome-wide survey and expression profiling of CCCH-zinc finger family reveals a functional module in macrophage activation. PLoS One 2008; 3: 1371.